Long-term Effect of Injection Treatment for Osteoarthritis in the Knee by Orthokin Autologous Conditioned Serum

Background Orthokin is an intra-articular autologous conditioned serum (ACS). Its use might have a beneficial biological effect on pain and function of osteoarthritis in the knee. However, earlier studies lack any consensus on its clinical application and disease modifying effect. Objective The aim of this study was to investigate the long-term effect of Orthokin injection treatment on prevention of surgical treatment for end-stage knee osteoarthritis. Study Design Prospective cohort study. Methods Patients of the previously published Orthokin cohort were contacted to determine whether any intra-articular surgical intervention or osteotomy of the study knee had taken place during the past decade. A log-rank test was performed to evaluate the differences in the survival distribution for the 2 types of intervention: Orthokin versus placebo. Results The survival distributions for the 2 interventions were not statistically significantly different, χ2(1) = 2.069, P = 0.150. After 7.5 ± 3.9 years, 46.3% of the placebo and 40.3% of the Orthokin group had been treated surgically. Conclusion The use of Orthokin in knee osteoarthritis patients did not result in a delay regarding surgical treatment. Clinical Relevance The intra-articular use of Orthokin does not seem to prevent or delay surgical intervention at 10 years after treatment for end-stage knee osteoarthritis.

Download Full-text

The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of Endometrioma

Reproductive Sciences ◽

10.1007/s43032-020-00453-7 ◽

2021 ◽

Author(s):

Sung Eun Kim ◽

Hyun-Hye Lim ◽

Dong-Yun Lee ◽

DooSeok Choi

Keyword(s):

Bone Mineral Density ◽

Surgical Treatment ◽

Bone Mineral ◽

Term Effect ◽

Mineral Density ◽

Long Term Effect

Download Full-text

Long-term effect of azithromycin in bronchiolitis obliterans syndrome

BMJ Open Respiratory Research ◽

10.1136/bmjresp-2019-000465 ◽

2019 ◽

Vol 6 (1) ◽

pp. e000465

Author(s):

C.Tji-Joong Gan ◽

Chris Ward ◽

Gerard Meachery ◽

James Laurence Lordan ◽

Andrew J Fisher ◽

...

Keyword(s):

Overall Survival ◽

Placebo Group ◽

Bronchiolitis Obliterans ◽

Bronchiolitis Obliterans Syndrome ◽

Term Effect ◽

Rank Test ◽

Open Label ◽

Log Rank Test ◽

Long Term Effect

IntroductionAzithromycin stabilises and improves lung function forced expiratory volume in one second (FEV1) in lung transplantation patients with bronchiolitis obliterans syndrome (BOS). A post hoc analysis was performed to assess the long-term effect of azithromycin on FEV1, BOS progression and survival .MethodsEligible patients recruited for the initial randomised placebo-controlled trial received open-label azithromycin after 3 months and were followed up until 6 years after inclusion (n=45) to assess FEV1, BOS free progression and overall survival.ResultsFEV1 in the placebo group improved after open-label azithromycin and was comparable with the treatment group by 6 months. FEV1 decreased after 1 and 5 years and was not different between groups. Patients (n=18) with rapid progression of BOS underwent total lymphoid irradiation (TLI). Progression-free survival (log-rank test p=0.40) and overall survival (log-rank test p=0.28) were comparable. Survival of patients with early BOS was similar to late-onset BOS (log-rank test p=0.74).DiscussionLong-term treatment with azithromycin slows down the progression of BOS, although the effect of TLI may affect the observed attenuation of FEV1 decline. BOS progression and long-term survival were not affected by randomisation to the placebo group, given the early cross-over to azithromycin and possibly due to TLI in case of further progression. Performing randomised placebo-controlled trials in lung transplantation patients with BOS with a blinded trial duration is feasible, effective and safe.

Download Full-text